Study on the sensitivity of colon cancer cells for Oxaliplatin enhanced by RNA interference in the expression of vascular endothelial growth factor receptor-2
YANG Ping WEI Jianchang CHEN Huacui ZHANG Tong ZENG Shanqi CAO Jie
Department of Gastrointestinal Surgery, Guangzhou First People's Hospital Guangzhou Digestive Diseases Center, Guangzhou First People's Hospital, Guangdong Province, Guangzhou 510180, China
Abstract：Objective To study the inhibitory effect of RNA interference in the expression of vascular endothelial growth factor receptor-2 (VEGFR-2) for the growth of human colon cancer cells and the chemosensitive effect of Oxaliplatin. Methods The expression plasmid of small interferon RNA (siRNA) targeting VEGFR-2 gene was constructed and human colon cancer cell line SW480 was transfected. The effect of VEGFR-2 siRNA for the expression of human colon cancer cells SW480 VEGFR-2 mRNA and protein was detected by RT-PCR and Western blot. The effect of siRNA or combining with Oxaliplatin for the cell proliferation and apoptosis was detected by MTT assay and flow cytometry. Results The mRNA and protein expression of VEGFR-2 were significantly down-regulated by VEGFR-2 siRNA (P ＜ 0.05). The combination of VEGFR-2 siRNA and Oxaliplatin could slowdown the growth of colon cancer cells, inhibit the proliferation, and significantly increase the inhibition of cell proliferation and apoptosis (P ＜ 0.05). Conclusion Silencing VEGFR-2 gene by the siRNA technology can inhibit the proliferation of SW480 cells, induce the apoptosis of SW480 cell, and enhance the chemotherapy sensitivity of Oxaliplatin for human colon cancer cells.
杨平 魏建昌 陈华翠 张通 曾山崎 曹杰. RNA干扰血管内皮生长因子受体2基因表达提高结肠癌细胞对奥沙利铂敏感性的研究[J]. 中国医药导报, 2017, 14(20): 16-19.
YANG Ping WEI Jianchang CHEN Huacui ZHANG Tong ZENG Shanqi CAO Jie. Study on the sensitivity of colon cancer cells for Oxaliplatin enhanced by RNA interference in the expression of vascular endothelial growth factor receptor-2. 中国医药导报, 2017, 14(20): 16-19.
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Deng Y，Chi P，Lan P，et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer：initial results of the Chinese FOWARC multicenter，open-label，randomized three-arm phase Ⅲ trial [J]. J Clin Oncol，2016，34（27）：3300-3307.
[3] Dong H，Yao L，Bi W，et al. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells [J]. Cancer Res Ther，2015，11（4）：717-722.
[4] 韩高雄，蔡明，王国斌，等.Livin靶向SiRNA协同5-氟尿嘧啶对大肠癌细胞的化疗增敏作用[J].中华实验外科杂志，2009，26（9）：1159-1162.
[5] 康从民，王大伟，吕英涛，等.血管内皮生长因子受体-2 所介导信号通路的研究进展[J].生物化学与生物物理进展，2009，36（10）：1267-1274.
[6] Yang F，Tang X，Riquelme E，et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy [J]. Cancer Res，2011， 71（16）：5512-5521.
[7] Silva SR，Bowen KA，Rychahou PG，et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis [J]. Int J Cancer，2011，128（5）：1045-1056.
[8] 梁文龙，曹杰，杨平，等.藤黄酸对人结肠癌SW480细胞裸鼠移植瘤生长及血管生成的影响[J].广东医学，2014，（16）：2498-2501.
[9] 杨平，曹杰，张通，等.藤黄酸对人结肠癌SW480细胞增殖及VEGFR2表达的影响[J].中国中医基础医学杂志，2012，18（5）：520-522.
[10] Shin SJ，Jung M，Jeung HC，et al. A phase I pharmacokinetic study of TSU-68（a multiple tyrosine kinase inhibitor of VEGFR-2，FGF and PDFG）in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy [J]. Invest New Drugs，2012，30（4）：1501-1510.
[11] Paré-Brunet L，Sebio A，Salazar J，et al. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemo?鄄therapy [J]. Pharmacogenomics J，2015，15（5）：397-404.
[12] Chen M，May BH，Zhou IW，et al. Oxaliplatin-based chemo?鄄therapy combined with traditional medicines for neutro?鄄penia in colorectal cancer：A meta-analysis of the contributions of specific plants [J]. Crit Rev Oncol Hematol，2016， 105：18-34.
[13] Petrelli F，Coinu A，Ghilardi M，et al. Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer：a systematic review and pooled analysis of published trials [J]. Am J Clin Oncol，2015，38（2）：227-233.
[14] Martinez-Balibrea E，Martínez-Cardús A，Ginés A，et al. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance [J]. Mol Cancer Ther，2015，14（8）：1767-1776.
[15] Ma JL，Zeng S，Zhang Y，et al. Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin [J]. Tumour Biol，2016，37（5）：6177-6184.
[16] 陈爱平，张晶，刘晖，等.表皮生长因子受体表达与卵巢癌血管生成及化疗耐药的关系[J].中华肿瘤杂志，2009， 31（1）：48-52.
[17] Liu Y，Guo Q，Zhang H，et al. Effect of siRNA-Livin on drug resistance to chemotherapy in glioma U251 cells and CD133 ＜ sup ＞ + ＜ /sup ＞ stem cells [J]. Exp Ther Med，2015，10（4）：1317-1323.
[18] B?覿umer S，B?覿umer N，Appel N，et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer [J]. Clin Cancer Res，2015，21（6）：1383-1394.
[19] Montazami N，Kheir Andish M，Majidi J，et al. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells [J]. Cell Mol Biol，2015，61（2）：98-103.
[20] Mezquita B，Pineda E，Mezquita J，et al. LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET [J]. Mol Carcinog，2016，55（5）：411-419.
[21] Kessler T，Sahm F，Blaes J，et al. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma [J]. Oncotarget，2015，6（31）：31050-31068.
2017, Vol. 14 
京公网安备 11010502046598号